Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity

Thrombosis and Haemostasis

Volumn 75, Issue 5, 1996, Pages 808-815

  Charlton, Peter A ^a   Faint, Richard W ^a   Bent, Fiona ^a   Bryans, Justin ^a   Chicarelli Robinson, Inês ^a   Mackie, Lan ^b   Machin, Samuel ^b   Bevan, Paul ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; UROKINASE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT LYSIS; CAROTID ARTERY THROMBOSIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; THROMBOGENESIS; THROMBOSIS;

EID: 0029894647     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650371     Document Type: Article

References (58)

1. Declerck PJ, Julian-Vague I, Félez J, Wiman B. Pathophysiology of fibrinolysis. Journal of Internal Medicine 1994; 236: 425-32.
2. Krishnamuni C, Alving BM. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Sem Thromb Hemost 1992; 18: 67-80.
3. Schneiderman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends in Cardiovascular Med 1991; 1: 99-102.
4. Edelberg JM, Sane DC, Pizzo SV. Vascular regulation of plasminogen activator inhibitor-1 activity. Sem Thromb Hemost 1994; 20: 319-23.
5. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-66.
6. Sancho E, Declerck PJ, Price NC, Kelly SM, Booth NA. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate and cleaved forms. Biochemistry 1995; 34: 1064-9.
7. Patston PA, Gettins PGW, Schapira M. Serpins are suicide substrates: Implications for the regulation of proteolytic pathways. Sem Thromb Hemost 1994; 20: 410-6.
8. Björquist P, Brohlin M, Ehnebom J, Ericsson M, Kristiansen C, Pohl G, Deinum J. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochemica et Biophysica Acta 1994; 1209: 191-202.
9. Reilly TM, Mousa SA, Seetharam R, Racanelli AL. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional and biological aspects. Blood Coagulation and Fibrinolysis 1994; 5: 73-81.
10. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial cell type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
11. Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 1990; 265: 109-13.
12. van Meijer M, Klein Gebbink R, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Letters 1994; 352: 342-6.
13. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
14. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-17,
15. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thrombosis Research 1993; 72: 413-21.
16. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
17. Booth NA, Croll A, Bennett B. The activity of plasminogen activator inhibitor-1 (PAI-1) of human platelet. Fibrinolysis 1990; 4 (suppl 2): 138-40.
18. Stringer HAR, van Swieten P, Heijnen HFG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arteriosclerosis and Thrombosis 1994; 14: 1452-8.
19. Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex vivo lysibility. Thromb Haemost 1992; 67: 101-5.
20. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli: Circulation 1994; 89: 2715-21.
21. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost 1992; 68: 60-3.
22. 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-6.
23. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-6.
24. Levi M, Biemond BJ, van Zonneveld A-J, ten Cale JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
25. Abrahamsson T, Björquist P, Deinum J, Ehnebom J, Hulander M, Legnehed A, Matsson C, Nerme V, Westin-Eriksson A, Åkerblom B. An antibody fragment against PAI-1 inhibits PAI-1 activity and stimulates fibrinolysis in vitro and in vivo. Fibrinolysis 1994; 8 (suppl 2): 55-6.
26. Gram J, Kluft C, Jespersen J. Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 1987; 58: 817-21.
27. Verheugt FW, ten Cate JW, Sturk A, Imandt L, Verhorst PM, van Eenige MJ, Verwey W, Roos JP: Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 1987; 59: 1075-9.
28. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
29. Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arteriosclerosis Thrombosis 1993; 13: 415-20.
30. Gray RP, Yudkin JS, Patterson L. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228-32.
31. Åstedt B, Casslén B, Lecander I, Nilsson L, Norgren L Rebound increase of PAI-1 following local intra-arterial rt-PA infusion, a possible cause of occlusion. Blood Coagulation and Fibrinolysis 1993; 4: 563-7.
32. Aznar J, Estellés A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994; 24: 24-51.
33. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localisation and production of plasminogen activator inhibitor- 1 in human healthy and atherosclerotic arteries. Arteriosclerosis and Thrombosis 1993; 13: 1090-100.
34. Jorgensen M, Bonnevie-Nielsen V. Increased concentration of the fastacting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-80.
35. Patrassi GM, Sartori MT, Saggiorato G, Boeri G, Girolami A. Familial thrombophilia associated with high levels of plasminogen activator inhibitor. Fibrinolysis 1992; 6: 99-103.
36. Grimaudo V, Bachmann F, Hauert J, Christe MA, Kruithof EK. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost 1992; 67: 397-401.
37. Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.
38. Diéval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-32.
39. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
40. Bick RL, Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Sem Thromb Hemost 1994; 20: 109-32.
41. Fay WP, Shapiro AD, Shin JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
42. Wieczorek I, Ludlam CA, Fox KAA. Tissue-type plasminogen activator inhibitor and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am J Cardiol 1994; 74: 424-9.
43. Chandler WL, Stratton JR. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Am J Clin Pathol 1994; 102: 248-52.
44. de Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 1994; 71: 504-7.
45. Cigolini M, Targher G, Seidell JC, Schiavon R, Manara F, Zenti MG, Mattioli C, De Sandre G. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis 1994; 106: 139-47.
46. Patston PA, Schapira M. Low-Affinity heparin stimulates the interaction of plasminogen activator inhibitor-1 by thrombin. Blood 1994; 84: 1164-72.
47. Nilsson K, Rosén S, Friberger P. A new kit for the determination of tissue plasminogen activator and its inhibitor in blood. Fibrinolysis 1987; 1: 163-8.
48. Gallimore MJ, Tyler HM, Shaw JTB. The measurement of fibrinolysis in the rat. Thromb Diath Haemorrh 1971; 26: 295-310.
49. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1971; 26: 407-10.
50. Jansen JWCM, van Giezen JJJ, Dreteler GH. Correlation of blood clot lysis with tissue t-PA activity. Fibrinolysis 1992; 6 (suppl 3): 76-7.
51. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
52. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2(8549): 3-9.
53. Vaughan DE, Declerck PJ, Reilly TM, Park K, Collen D, Fasman GD. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). Biochimica et Biophysica Acta 1993; 1202: 221-9.
54. MacCallum PK, Meade TW, Howath DJ. Determinants of the dilute whole blood clot lysis time (DCLT). Brit J Haematol 1995; 89 (Suppl 1): 28a.
55. Knabb RM, Chiu AT, Reilly TM. Effects of recombinant plasminogen activator inhibitor type1 on fibrinolysis in vitro and in vivo. Thromb Res 1990; 59: 309-17.
56. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, "mixed" and arterial thrombosis, and its effect on the tail transection bleeding time. Br J Pharmacol 1994; 113: 1209-14.
57. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Circulation 1995; 91: 1175-81.
58. Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 1992; 79: 417-29.